DailyIQ
|
Sector:Consumer DefensiveAll sectors
Last updated 1 minute ago

KMB·Kimberly-Clark Corporation

$.
+. (+.%)
After Hours
High
$108.79
Open
$108.00
Market Cap
35.97B
52W High
$137.46
Low
$107.63
P. Close
$108.51
P/E
16.98
52W Low
$92.42
Fwd P/E
54.08
DailyIQ Est.
$116.52
Technical Score (1D)
59
BUY
News Sentiment
67
BULLISH
UBS has lifted its price target for Kimberly‑Clark to $115 from $106 while keeping a neutral rating, signaling confidence in the company’s steady cash flow and dividend policy. The upgrade comes amid expectations of earnings growth and a stable dividend outlook, but UBS remains cautious about potential market volatility and competitive pressures. Jim Simons’ Renaissance Technologies has highlighted KMB as a top dividend stock, underscoring the firm’s attractive yield and consistent cash generation. The endorsement from a prominent quantitative fund may reinforce investor confidence in KMB’s dividend reliability over the next 10 trading days. KMB’s newly launched Arbex joint venture with Suzano, a $3.4 billion entity, expands its international tissue and hygiene footprint and could provide new growth avenues while maintaining a robust dividend policy. The venture’s independent operation is expected to enhance supply‑chain efficiencies and broaden KMB’s consumer and professional segments, potentially supporting future earnings. Pricing headwinds continue to pressure margins, but recent productivity gains and cost‑control initiatives could offset these pressures, a factor that analysts will weigh in the upcoming earnings. KMB will announce its Q2 2026 results on August 4, and the guidance and any revisions to future earnings expectations will be a key watch item for traders. In the short term, traders should monitor how the company’s earnings release reflects the Arbex launch, margin dynamics, and any updates to its dividend policy.
Earnings Summary
Kimberly‑Clark Corporation is a consumer staples company that produces and distributes personal care products such as diapers, tissues, and feminine hygiene items, operating within the consumer defensive sector and the household & personal products industry. In its most recent reporting cycle, the company reported Q4‑2025 earnings of $1.86 per share on revenue of $4.08 billion, following a Q3‑2025 EPS of $1.82 on $4.15 billion, a Q2‑2025 EPS of $1.92 on $4.163 billion, and a Q1‑2025 EPS of $1.93 on $4.84 billion; the firm’s Q4‑2024 EPS of $1.50 on $4.928 billion set a baseline that the company has largely missed in recent quarters, with EPS beating consensus estimates in Q1‑2025, Q2‑2025, Q3‑2025, and Q4‑2025 but missing guidance in Q4‑2024 and Q1‑2026, while revenue has trended downward from $4.928 billion in Q4‑2024 to $4.08 billion in Q4‑2025 before a modest uptick to $4.163 billion in Q1‑2026, indicating a gradual decline in top‑line growth. Historically, Kimberly‑Clark has maintained steady cash flow and dividend policy, with a 80 % payout ratio and consistent dividend increases, but recent pricing headwinds have pressured margins, and the company’s earnings have shown a mix of beats and misses that reflect the impact of cost‑control initiatives and competitive pricing. Recent news highlights UBS’s lift of the price target to $115 from $106, the launch of the Arbex joint venture with Suzano that expands the company’s international tissue and hygiene footprint, and recognition by Jim Simons’ Renaissance Technologies as a top dividend stock; these developments suggest confidence in the firm’s dividend reliability and potential growth from the joint venture, but also underscore the importance of margin management. Investors should watch for the Q2‑2026 earnings release, which will provide guidance on revenue, EPS, and dividend sustainability, as well as the first‑quarter sales rollout of the Arbex venture and any updates to the company’s cost‑control initiatives, as these factors will be key to assessing the firm’s ability to maintain its dividend policy amid pricing pressures.

EPS

EstBeatMiss
$1.59$1.73$1.86$2.00$2.13Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.01 - -
Q1'26$2.07$1.97-4.9%
Q4'25$1.83$1.86+1.7%
Q3'25$1.75$1.82+3.9%
Q2'25$1.66$1.92+16.0%
Q1'25$1.89$1.93+2.0%

Revenue

EstBeatMiss
$4.0B$4.2B$4.5B$4.7B$5.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.3B - -
Q1'26$4.3B$4.2B-2.1%
Q4'25$4.1B$4.1B-1.2%
Q3'25 - $4.2B -
Q2'25 - $4.2B -
Q1'25 - $4.8B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

KMB Stock Snapshot

KMB is currently trading at $108.48, giving Kimberly-Clark Corporation a market cap of 35.97B and a P/E ratio of 17.0. Today's range spans $107.63–$108.79, with shares opening at $108.00 and moving down $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 67/100.

Over the past year KMB has traded between $92.42 and $137.46 - the current price is +17.4% off the 52-week low and -21.1% from the high. 22 analysts cover the stock with a Hold consensus and a mean 12-month target of $115.47 (range $90.00–$162.00), implying upside of +6.4%.

KMB is in a holding pattern - 59/100 technical score, HOLD signal, price at $108.48 (in the lower half of its 52-week range), sentiment bullish at 67/100. (P/E: 17.0) At 35.97B in Consumer Defensive market cap, HOLD phases like this are where the thesis is re-evaluated and position sizing decisions get made by both longs and shorts. Annual range: $92.42–$137.46. The next catalyst, not the current setup, determines the exit from this range.

The 52-week range of $92.42–$137.46 for KMB provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $108.48 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 59/100 and bullish news backdrop (67/100) don't break the tie yet, but they narrow the probability distribution toward the upside.